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Abstract
Background: Home parenteral nutrition (HPN) is a life-preserving therapy for patients with chronic intestinal failure
(CIF) indicated for patients who cannot achieve their nutritional requirements by enteral intake. Intravenously
administered lipid emulsions (ILEs) are an essential component of HPN, providing energy and essential fatty acids,
but can become a risk factor for intestinal-failure-associated liver disease (IFALD). In HPN patients, major effort is
taken in the prevention of IFALD. Novel ILEs containing a proportion of omega-3 polyunsaturated fatty acids
(n-3 PUFA) could be of benefit, but the data on the use of n-3 PUFA in HPN patients are still limited.
Methods/design: The HOME study is a prospective, randomized, controlled, double-blind, multicenter, international
clinical trial conducted in European hospitals that treat HPN patients. A total of 160 patients (80 per group) will
be randomly assigned to receive the n-3 PUFA-enriched medium/long-chain triglyceride (MCT/LCT) ILE (Lipidem/
Lipoplus® 200 mg/ml, B. Braun Melsungen AG) or the MCT/LCT ILE (Lipofundin® MCT/LCT/Medialipide® 20%, B.
Braun Melsungen AG) for a projected period of 8 weeks. The primary endpoint is the combined change of liver
function parameters (total bilirubin, aspartate transaminase and alanine transaminase) from baseline to final visit.
Secondary objectives are the further evaluation of the safety and tolerability as well as the efficacy of the ILEs.
Discussion: Currently, there are only very few randomized controlled trials (RCTs) investigating the use of ILEs in
HPN, and there are very few data at all on the use of n-3 PUFAs. The working hypothesis is that n-3 PUFA-enriched
ILE is safe and well-tolerated especially with regard to liver function in patients requiring HPN. The expected
outcome is to provide reliable data to support this thesis thanks to a considerable number of CIF patients,
consequently to broaden the present evidence on the use of ILEs in HPN.
Trial registration: ClinicalTrials.gov, ID: NCT03282955. Registered on 14 September 2017.
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Background
Home parenteral nutrition and chronic intestinal failure
Home parenteral nutrition (HPN) is indicated for pa-
tients who cannot meet their nutritional requirements
by enteral intake and who are able to receive therapy
outside an acute care setting [1]. A reduction of the gut
function below the minimum necessary for the absorp-
tion of macronutrients and/or water and electrolytes,
such that intravenously administered supplementation
(IVS) is required to maintain health and/or growth, is
defined as intestinal failure [2]. For patients with chronic
intestinal failure (CIF) who require IVS for a long
period, or for the rest of their life, HPN is currently the
primary therapy [1].
The management of parenteral nutrition (PN) supply
of patients at home varies among different countries and
even between hospitals within the same country, but is
always subject to thoroughly organized processes
adapted to patients’ needs and preferences. Also, the nu-
tritional and fluid needs of HPN patients are very vari-
able and should be determined on the basis of individual
patient assessments [3].
Intravenously administered lipid emulsions and liver
function
Intravenously administered lipid emulsions (ILEs) are a
main source of energy and essential fatty acids (EFA), by
which they are an essential component of PN and should
be provided to almost all patients dependent on HPN
[4]. The first ILEs developed were derived from cotton
seed oil or soybean oil (SO) which have a high content
of the omega-6 polyunsaturated fatty acid (n-6 PUFA)
linoleic acid (LA, 18:2n-6). SO-based ILE – commonly
called “long-chain triglycerides” (LCT) – in particular in
higher doses, are considered to cause several nutritional
complications due to the pro-inflammatory metabolites
of LA and the content of potentially toxic phytosterols
[5, 6]. In order to decrease the amount of n-6 PUFA,
physical mixtures, consisting of 50:50 SO and coconut
oil (containing mainly medium-chain triglycerides
(MCT)), structured-lipid (LCT/MCT) and olive oil
(OO), ILE have been developed. Several studies have
suggested that this so-called second generation of ILEs
may have a lower impact on liver function than pure
SO-LCT ILEs [7, 8]. Newer ILEs are more complex and
include a proportion of fish oil (FO)/omega-3 (n-3)
PUFA, i.e., eicosapentaenoic acid (EPA, C20:5n-3) and
docosahexanoic acid (DHA, C22:6n-3). EPA and DHA
have been described to possess favorable immunomodu-
latory and anti-inflammatory properties and their use
has been shown to be of benefit in various patient popu-
lations [9–14].
In HPN patients a major effort is made towards the
prevention of, or if it has already occurred, the treatment
of, intestinal-failure-associated liver disease (IFALD).
There is no standardized definition, but the term IFALD
refers to liver injury caused by several factors relating to
CIF, including but not limited to PN. The source and
the amount of the lipid component of the PN admixture
are under special focus. For long-term administration (>
6 months) SO-based ILE should comprise no more than
1 g lipid/kg body weight (BW) per day to prevent hepatic
toxicity, i.e., IFALD [15]. Decreasing the amount of lipid,
however, is often not an appropriate strategy, in particu-
lar if carbohydrates would need to be provided in excess
to achieve the total energy goal. Thus, newer ILEs with a
more favorable n-6:n-3 PUFA ratio might be promising
options for long-term use.
In the past few years, several studies on FO-based ILEs
have been conducted to evaluate their potential benefits
in treatment and prevention of IFALD, in particular in
pediatric patients [16–18]. For adult patients, data on
the use of n-3 PUFA ILEs in HPN are still very limited
[2, 19]. Some case reports showing beneficial effects
from FO/n-3-enriched ILEs in the prevention or treat-
ment of IFALD [20–22] and case series [23, 24] are
available. A systematic literature review published in
2018 (search results until November 2015) identified
only three randomized controlled trials (RCTs) investi-
gating the effects of ILE in adult patients, altogether cov-
ering 110 patients [25]. Just one of them studied an n-3
PUFA-containing ILE [26]. In this study in 73 patients,
lower values of total bilirubin, alanine transaminase
(ALT) and aspartate transaminase (AST) were detected
after 4 weeks of treatment with a mixed FO-containing
ILE compared to SO. A recently published study ob-
served 67 patients for 12 months on HPN and compared
four ILEs (LCT n = 14, MCT/LCT n = 18, OO/LCT n =
17, and LCT/MCT/OO/FO n = 16) [27]. They showed
that all four ILEs were safe and had comparable influ-
ence on liver function with a slightly better effect from
OO/LCT, however recognizing some limitations in in-
terpretation given disparate initial patient characteristics.
Study objective
This clinical trial aims to investigate the safety and toler-
ability of an n-3 PUFA-enriched ILE in comparison to
an LCT/MCT ILE for a projected period of 8 weeks with
special regard to liver function in stable adult HPN
patients.
The working hypothesis is that n-3 PUFA-enriched
ILE is safe and well-tolerated especially with regard to
liver function in patients requiring HPN. The expected
outcome is to provide reliable data to support this thesis
thanks to a considerable number of CIF patients, conse-
quently to broaden the present evidence on the use of
ILEs in HPN.
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Methods/design
Study design
The HOME study is a prospective, randomized, con-
trolled, double-blind, international, multicenter, phase
IV clinical trial with two parallel groups to be conducted
in European hospitals that treat HPN patients. It aims to
investigate safety and tolerability of an n-3 PUFA-
enriched MCT/LCT ILE in stable adult CIF patients on
long-term HPN and to show its non-inferiority com-
pared to an MCT/LCT ILE with regard to liver function.
A total of 160 (80 per group) eligible patients will be
randomly assigned to receive the n-3 PUFA-enriched
MCT/LCT ILE or the MCT/LCT ILE within their PN
regimen.
The SPIRIT (Standard Protocol Items: Recommenda-
tions for Interventional Trials) Checklist for this study
can be found in Additional file 2.
Setting
The settings of the study are the surgical or gastro-
enterological outpatient clinics of the participating hos-
pitals, where patients are cared for and monitored;
however, the PN regimen including the Investigational
Product (IP) is administered to patients at their homes.
The processes of HPN supply can differ widely between
countries and even between hospitals within the same
country, but it is intended to follow the local standard
procedures in this multicenter study as far as possible.
The recruitment period was initially set at 18 months.
Trial population and eligibility criteria
Patients will be screened from the existing patient pool
of the participating hospitals and must meet the follow-
ing inclusion criteria to be considered eligible for the
trial: informed consent has to be available, male or fe-
male patients ≥ 18 years of age with CIF receiving HPN
including lipids in whom the parenteral macronutrients
have not been changed by more than 10% for at least 6
months, and patients must receive ≥ 3.0 g lipids/kg BW
per week.
It was decided to present the dose of lipids is pre-
sented as grams per kilogram (g/kg) BW/week as the ac-
cepted policy in the designing of the HPN regimen is to
reduce PN infusion days to a necessary minimum per
week, maintaining the obligatory provision at the same
time.
A patient who meets any of the following criteria will be
excluded from participation: (1) persistent high total biliru-
bin values in medical history of the last 6 months (>
40 μmol/l), (2) interruption of PN for longer than four con-
tinuous weeks in the preceding 6 months, (3) history of
cancer and anti-cancer treatment within the last 2 years, (4)
hypersensitivity to egg, fish, peanut or soybean protein or
to any of the active substances or excipients, (5) treatment
with teduglutide in the past or currently, (6) contraindica-
tions to IPs (if available from medical records), which are
severe hyperlipidemia including severe hypertriglyceridemia
(≥ 1000mg/dl or 11.4mmol/l), severe coagulopathy, intra-
hepatic cholestasis, severe hepatic insufficiency, severe renal
insufficiency in the absence of renal replacement therapy,
acute thromboembolic events, fat embolism, aggravating
hemorrhagic diatheses and metabolic acidosis, (7) general
contraindications to PN (if available from medical records)
including unstable circulatory status with vital threat (states
of collapse and shock), acute phase of cardiac infarction or
stroke, unstable metabolic conditions (e.g., decompensated
diabetes mellitus, severe sepsis, coma of unknown origin),
inadequate cellular oxygen supply, disturbances of the elec-
trolyte and fluid balance (e.g., hypokalemia and hypotonic
dehydration), acute pulmonary edema, decompensated car-
diac insufficiency, (8) positive test for HIV, hepatitis B or C
(from medical history), (9) known or suspected drug or al-
cohol dependency, (10) patients who are unwilling or men-
tally and/or physically unable to adhere to study
procedures, (11) participation in another interventional
clinical trial in parallel or within 3 months prior to the start
of this clinical trial, (12) any medical condition that in the
opinion of the investigator might put the subject at risk or
interfere with patient participation, (13) women of child-
bearing potential testing positive on standard pregnancy
test (urine dipstick), (14) lactating women, (15) women of
childbearing potential who do not agree to apply adequate
contraception and (16) persons of legal age who are the
subject of a legal protection measure or who are unable to
express their consent.
Investigational Products (IPs)
The test IP Lipidem/Lipoplus® 200 mg/ml (B. Braun
Melsungen AG, subsequently referred to as Lipidem®
200 mg/ml) is a milky-white oil-in-water emulsion for
infusion. One liter of emulsion contains 100.0 g MCT,
80.0 g LCT and 20.0 g n-3 PUFA and provides the
following amounts of EFAs: 38.4–46.4 g linoleic acid (n-
6 PUFA), 4.0–8.8 g alpha-linolenic acid (n-3 PUFA), and
8.6–17.2 g EPA and DHA in sum. Additional excipients
are all-rac-α-tocopherol, egg lecithin, glycerol, ascorbyl
palmitate, 2.6 mmol/l sodium as sodium hydroxide and
sodium oleat and water for injection. The energy content
of 1000 ml Lipidem® 200 mg/ml is 7990 kJ ≈ 1910 kcal,
the theoretical osmolality is approximately 410 mOsm/
kg and pH range is 6.5–8.5 (NaOH or HCl < 0.5 mmol/l
for adjustment to pH 7.4).
The reference IP Lipofundin® MCT/LCT/Medialipide®
20% (100 mg/ml + 100 mg/ml) (B. Braun Melsungen AG,
subsequently referred to as Lipofundin® MCT/LCT 20%)
is a milky-white oil-in-water emulsion for infusion. One
liter contains: 100 g MCT and 100 g LCT and provides
the following amounts of EFAs: 48.0–58.0 g linoleic acid
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(n-6 PUFA) and 5.0–11.0 g alpha-linolenic acid (n-3
PUFA) (n-3 PUFA). Additional ingredients are all-rac-α-
tocopherol, egg lecithin, glycerol, sodium oleat and water
for injection. The energy content of 1000 ml Lipofundin®
MCT/LCT 20% is 8095 kJ ≈ 1935 kcal, the theoretical
osmolarity is approximately 380mOsm/l and pH range
is 6.5–8.5 (NaOH or HCl < 0.5 mmol/l for adjustment to
pH 7.4).
The administration of the IP is performed intraven-
ously. The IP will be delivered as the lipid part of the
PN. Besides the lipid, PN contains glucose, amino acids,
electrolytes, trace elements and vitamins and will be ad-
ministered according to the individual patient’s normal
prescription. The weekly dose of IP will be at least 3.0 g
lipid/kg BW (corresponding to 15ml emulsion/kg BW).
Randomization, blinding and unblinding
Eligible patients will receive a patient number indicating
country, study site and randomization number. The
randomization to either treatment will be in a 1:1 ratio
with stratification for study center. A list of treatment
assignments has been generated prior to the initiation of
the study using consecutive blocks with the order of
assignments chosen at random by an independent bio-
metrician. The study is double-blind.
The processes of HPN supply differ between the study
sites. The PN is prepared either in stocks as all-in-one
admixtures in the hospital pharmacy or a compounding
unit (CU) of a pharmacy service company or it is pro-
vided in multi-chamber bags to which the IP is added or
it is mixed from the single nutrients on a daily base. In
this multicenter clinical trial it is intended to follow the
hospitals’ local standard procedures of PN supply as far
as possible. This requires blinded IP in those sites where
the patient will admix the PN including the lipid by
themselves. The production of the blinded IP is at the
sponsor site and the sponsor’s Qualified Person for IP is
responsible for blinding the samples prior to shipment
to the sites. In study sites where either the hospital phar-
macy or a CU is involved in preparing the all-in-one PN
admixtures including the IP as the lipid part, unblinded
IP will be delivered to the pharmacy/CU. The PN
including the lipid will be prepared and provided to the
participating patient as in routine practice. Treatment
allocation is realized by randomization envelopes, which
are issued by the independent statistician and provided
to an unblinded pharmacist (or a delegate). Of note, the
blinding of the investigators or other staff outside the
pharmacy/CU will be maintained throughout the
complete process. Finally, the PN bag label of the phar-
macy/CU will not reflect which lipid is used, but only
the amount of lipid. Thus, it is guaranteed also that the
patient is kept blinded.
Based on the randomization, list sets of emergency
envelopes have been prepared for each participating site
and the sponsor in case unblinding becomes necessary.
Except for emergency reasons, the study will only be
unblinded after closure of the database and determin-
ation of the analysis populations in a blinded data review
meeting.
Interventions and procedures
The schedule of enrollment, interventions and assess-
ments is shown in Fig. 1 (SPIRIT Figure).
Screening and randomization
Patients will be enrolled for the trial from the existing
patient pool of the participating clinic and information
about the trial can be provided in advance by phone and
with information materials. After obtaining informed
consent, the patient will be checked for eligibility. If all
inclusion criteria are met and all exclusion criteria are
excluded the patient will be randomized.
Baseline visit
The baseline assessment is performed after randomization
on the day of screening. Collected and generated data will
be recorded in electronic Case Report Forms (eCRFs). Pa-
tient characteristics (demographic data, anamnesis and
physical examination) and vital signs will be documented.
Routine blood samples are taken and results for hepatic
function, blood count and coagulation as well as biochem-
ical parameters will be documented for the trial. For cen-
tral laboratory analysis of the primary variable and the
fatty acid (FA) pattern in red blood cells (RBCs) and
plasma, additional blood samples are drawn and proc-
essed. Blood samples are taken no sooner than 3 h after
completion of the last PN infusion. Patients will be asked
to complete a quality of life (QoL) questionnaire (EQ-5D-
5 L™, EuroQol Group, (Herdman et al., 2011)). Concomi-
tant medication and adverse events (AEs) will be moni-
tored and recorded continuously from study start
(randomization) throughout the duration of patient’s
study participation.
Patients are provided with a diary for documentation
of IP administration on a daily base until visit 1. The
patient has to enter date, start and end time of infusion
of each PN bag containing the IP as well as the weight
of the bag before and after infusion. Furthermore, the
intake of oily fish meals is recorded.
The PN regimen including IP will be prescribed and
prepared as needed. The infusion of IP will start within
1 week after baseline visit. If applicable, changes in
prescription will be documented throughout the course
of the study.
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STUDY PERIOD
Enrollment Baseline Visit 1 Visit 2(final visit)
TIMEPOINT Day 0 Day 0 4 weeks after start of IP
4 weeks after 
visit 1
ENROLMENT:
Patient information X
Informed consent X
Eligibility screening X
Pregnancy test X X X
Randomization X
INTERVENTIONS:
Administration of IP (start of IP 
infusion is within 1 week after Baseline)
ASSESSMENTS:
Demographic data X
Anamnesis X
Physical examination X
Vital signs X X
Body weight X X
Energy requirements X
Prescription of PN regimen X1
Blood samples X X2 X
Laboratory assessments
Hepatic function X X X
Blood count and coagulation X X X
Further biochemical parameters X X X
Fatty acid pattern in RBCs and 
plasma X X
Quality of life X X X
Documentation of IP infusion 
(patient dairy)
Treatment compliance based on 
patients entries X X
Concomitant medication
AEs
Study termination X
1 The PN treatment including IP will be prescribed until the final visit. If applicable, changes in prescription will be documented 
continuously throughout the course of the study.
2 No blood sample for central laboratory analysis of fatty acid pattern in RBCs and plasma will be taken.
Fig. 1 (See legend on next page.)
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Visit 1
The study visit 1 will be conducted 4 weeks after start of
IP infusions. The visit should be preferably the same day
of the week and time of day as the baseline visit. If this
is not possible, it should be the same interval between
PN infusion and visit day as it was for baseline (e.g., if
the baseline visit was after a day free of PN, visit 1
should also be after a day free of PN).
Depending on patient’s travel distance and
organizational circumstances, the study visit can be
scheduled around the intended visit date within a toler-
ance timeframe of − 3 days up to + 2 weeks.
All assessment of safety, efficacy and other variables
will be performed except blood draw for FA pattern and
the QoL questionnaire. The first part of the patient diary
will be collected and checked for accurateness and com-
pleteness. The data will be entered into the eCRF and
the second part of the patient diary will be handed out
for the treatment period until visit 2.
Visit 2 (final visit)
Visit 2 will be conducted 4 weeks after visit 1 and is the
final visit. As for visit 1 it should also be preferably the
same day of the week and time of day as the baseline
visit (and/or visit 1). If this is not possible, it should be
the same interval between PN infusion and visit day as it
was for visit 1. The tolerance timeframe for visit 2 is − 3
days up to + 2 weeks around the intended visit date. All
assessment of safety, efficacy and other variables will be
repeated at visit 2. The second part of the patient diary
will be collected. After visit 2 the study ends for the pa-
tient and no IP must be administered. The PN treatment
will continue according to the decision of the physician
with a regularly used ILE.
Study and treatment duration
The study starts with randomization and ends with the
final visit (visit 2). The IP administration will start within
1 week after randomization and the duration of treat-
ment with IP is projected to be a period of 8 weeks on
average.
Outcome measures
Primary outcome
The primary objective of the study is to prove safety and
tolerability of HPN with an n-3 PUFA-enriched ILE in
adult patients with CIF in need of long-term HPN. It
aims to show non-inferiority of the test IP in comparison
to the reference IP with regard to liver function.
The primary endpoint of the study is the change of
liver function parameters defined as the sum of the N (0,
1)-transformed differences in bilirubin, ALT and AST
from baseline to visit 2:
Δ ¼ BILI−Δ1
SD1
þ ALT−Δ2
SD2
þ AST−Δ3
SD3
;
where BILI = change of total bilirubin, Δ1 =mean change
of BILI, SD1 = standard deviation of change of BILI;
ALT = change of SGPT, Δ2 =mean change of ALT, SD2 =
standard deviation of change of ALT; AST = change of
SGOT, Δ3 =mean change of AST and SD3 = standard
deviation of change of AST.
Secondary outcomes
The secondary objectives are the further evaluation of
safety and efficacy. Secondary safety variables include pa-
rameters of hepatic function, blood count and coagula-
tion, blood biochemistry, triene:tetraene ratio calculated
from plasma FA pattern and AEs. Body mass index
(BMI) and FA pattern in plasma and RBCs are secondary
efficacy variables. Other secondary variables are demo-
graphic data, anamnesis and physical examination, vital
signs, calculated BW change, QoL according to EuroQol
Group EQ-5D™, concomitant medication, energy re-
quirements, PN prescription per week and treatment
compliance. Detailed secondary safety, efficacy and other
variables are listed in Additional file 1.
Concomitant medication, therapies
The following concomitant medications are allowed:
 Nutritional components (glucose, amino acids,
vitamins, trace elements and electrolytes) according
to the patient’s needs and investigator’s prescription
either in a two-chamber bag or in a compounded
all-in-one PN-bag to which the IP will be added
 Due to manufacturing/transportation steps there is a
time interval between the baseline visit and the first
administration of IP (maximum of 1 week). During
this time-frame the administration of the usually
prescribed lipid emulsion is allowed until the IP is
provided to the patient
(See figure on previous page.)
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trial (SPIRIT) Figure: HOME study visits. 1The parenteral nutrition (PN)
treatment including Investigational Product (IP) will be prescribed until the final visit. If applicable, changes in prescription will be documented
continuously throughout the course of the study. 2No blood samples for central laboratory analysis of fatty acid pattern in red blood cells and
plasma will be taken
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 Administration of concomitant medication as
clinically required, but always considering the IP’s
special warnings and precautions for use
The following concomitant medications are not
allowed:
 With the exception of the situation as described
above (maximum interval of 1 week after baseline
visit), the administration of lipid emulsions other
than IP
 Any dietary supplements containing n-3 PUFA in-
cluding, but not limited to, fish-oil capsules, enteral/
oral nutritional supplements containing fish-oil etc.
Safety evaluation and reporting of adverse events
Throughout the course of the clinical trial, from the mo-
ment of randomization until the last study visit, particu-
lar attention will be paid to all AEs including serious
AEs (SAEs). The investigator must record all AEs in de-
tail whether serious or not. SAEs have to be reported to
the sponsor within 24 h after the first knowledge that
they have occurred.
SAEs with suspicion of a causal relationship to the
study treatment (serious adverse reaction, SAR) that are
unexpected according to the available summaries of
product characteristics of Lipidem® 200 mg/ml and
Lipofundin® MCT/LCT 20% have to be considered as
Suspected Unexpected Serious Adverse Reactions (SUSA
Rs). SUSARs are subject to expedited reporting. The
sponsor will notify the competent authorities, Ethics
Committees and all investigators concerned about SUSA
Rs, in line with pertinent legal requirements.
The entire clinical study might be discontinued upon
an unexpected high frequency of (S)AEs/(S)ARs or the
occurrence of SUSARs. Individual patients might be
withdrawn by the investigator in case of (S)AEs leading
to non-acceptance of study continuation.
Statistical methods
Sample size calculation
The sample size calculation is based on the primary end-
point of the study, which is the change of liver function
parameters defined as the sum of the N (0,1)-trans-
formed differences from baseline in bilirubin, ALT and
AST after 8 weeks of treatment. It is the aim to demon-
strate non-inferiority of the test IP as compared to the
reference IP with respect to “deterioration in liver
function.” Because of the normality and equal variance,
the one-sided, two-sample t test will be applied. The
standard deviation of the specified endpoint was derived
from previous study data providing a standard deviation
of σ = 2.3029, so the non-inferiority margin for this study
is taken as σ/2, i.e., δ = 1.151. For the sample size
calculation the power was taken as 1 − β = 0.8 and the
significance set at α = 0.025, resulting in a sample size of
128 patients for two groups (64 per group). Assuming a
drop-out rate of 20%, a total of 160 patients should be
randomized in a ratio of 1:1 for assessment of the
primary endpoint.
Analysis populations
The All-Patients-Screened population will comprise all
patients who gave written informed consent to partici-
pate in the study. The Intention-To-Treat Set will com-
prise all randomized patients enrolled in the study. The
All-Patients-Treated Set will comprise all patients of the
ITT set who received at least one dose of the trial
medication.
Additionally, the Full Analysis Set (FAS) will comprise
all patients who received at least one dose of the trial
medication and from whom at least one efficacy meas-
urement is available after this dose. The Valid Case
Analysis Set (VCAS) will comprise all patients in the
FAS who did not show any major violations of the
protocol including the violations of the requirements of
study conduct.
Statistics
All programming of tables, figures, listings and statistical
analyses will be performed using a statistical software
package (SAS® version 9.4). Statistics will be performed in
accordance with the principles outlined by the guideline
E9 of the International Conference on Harmonization
(ICH) and will be outlined in detail in the statistical ana-
lysis plan that will be finalized before close of database.
The primary analysis will be performed for the VCAS
(FAS for sensitivity). No imputation will be performed.
The t test will compare the (one-sided) null hypothesis
(H0: ΔT ≥ ΔS + δ) against the alternative hypothesis (H1:
ΔT < ΔS + δ) on the level of 0.025, where ΔT and ΔS rep-
resent the increase of the primary endpoint upon T =
test and S = standard, respectively. Non-inferiority (with
non-inferiority margin σ = 1.151) can be concluded, if
the VCAS analysis yields an upper limit of the two-sided
95% confidence interval (or one-sided 97.5% confidence
interval) for the treatment contrast of the primary end-
point lower than 1.151 and if this result is confirmed by
the corresponding FAS analysis. Superiority of T vs. S,
i.e., H0: ΔT ≥ ΔS vs. H1: ΔT < ΔS, is demonstrated simul-
taneously if the upper limit of the confidence interval is
below zero for both the FAS analysis and the VCAS
analysis.
Given non-inferiority of T vs. S, breakdown of the
multiple primary endpoint to its components bilirubin,
ALT and AST, will be performed [28]. Further methods
are descriptive statistics including standard procedures
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for the comparison of two groups (t test, Mann-Whitney
U test, χ2 test).
Tests of secondary variables will be carried out in the
area of exploratory data analysis. Therefore, correspond-
ing p values are to be regarded as exploratory ones and
no adjustments for multiple testing will be made.
Data registration and monitoring
All data obtained in the context of the clinical trial are
subject to data protection. If personal data are stored
and processed, the requirements of pertinent data pro-
tection legislation will be observed.
Every effort will be made to collect all data points in
the study. The amount of missing data will be mini-
mized by appropriate management of the trial, proper
screening of subjects, and training of participating inves-
tigators and other authorized staff, monitors and study
manager.
The data generated in this study will be recorded using
a computerized system in accordance with applicable
regulations. The system will generate an individual eCRF
for each patient participating in the trial. The principal
investigator of each study site must ensure the accuracy,
completeness and timelines of the data entry in the sys-
tem. The eCRF system will guarantee compliance with
Code of Federal Regulations (CFR) 21 part 11, data
safety, communication security, limited access, user roles
and full audit trail.
Authorized, qualified clinical research associates will
visit the investigational sites at regular intervals as de-
fined in the monitoring plan to verify adherence to the
protocol and local legal requirements, to perform
source-data verification and to assist the investigator in
their study-related activities. Facilities that are involved
in IP handling and dispensing will also be visited regu-
larly for monitoring of IP accountability. In the case that
unblinded IP is used at the facility, an additional un-
blinded monitor will perform these visits. An independ-
ent audit at the study site may take place at any time
during or after the study.
Ethical and legal considerations
This clinical study will be conducted in accordance with
the ethical principles described in the Declaration of
Helsinki and in compliance with the protocol, Good
Clinical Practice (2001/20/EEC, CPMP/ICH/135/95),
designated standard operating procedures, and with local
legal and regulatory requirements in the countries in
which the study will be conducted. Before the start of
the trial, the trial protocol and all documents that are sub-
ject to review will be provided to the Ethics Committees/
Institutional Review Boards concerned, and to competent
national and local authorities by the sponsor or the inves-
tigator in line with national provisions. All substantial
protocol modifications will be submitted as substantial
amendments to these committees and competent
authorities.
Informed consent has to be obtained from all patients.
The patients will be advised that they have the right to
withdraw from the study at any time without prejudice,
and may be withdrawn at the investigator’s/sponsor’s
discretion at any time, when this is considered to be in
the interest of the patient.
Responsibilities
Responsibilities of investigators, monitors and sponsor of
the clinical trial regarding handling and storage of data,
planning, assessment and quality assurance are regulated
by the recommendations on “International Conference on
Harmonization Topic E6 Guideline for Good Clinical
Practice” and apply also to this clinical trial.
The costs necessary to perform the study have been
agreed upon with each investigator and are documented
in separate financial agreements which have been signed
by the hospital administration, the investigator and the
sponsor, prior to the study commencing.
The sponsor B. Braun Melsungen AG has taken out
subject insurance for all patients taking part in the trial.
Publication policy
The sponsor and principal investigators will agree on the
final study report. It is intended that the results of the
study may be published as scientific literature. In accord-
ance with generally recognised principles of scientific
collaboration, co-authorship with any sponsor personnel
will be discussed before submission of a manuscript to a
publisher. Results may also be used in submissions to
regulatory authorities. Information developed in this
clinical study may be disclosed as required to other in-
vestigators or any appropriate international regulatory
authorities. The sponsor will be provided with complete
test results and all data developed during this study.
Study registration
The study protocol was registered in the ClinicalTrials.
gov Protocol Registration and Results System, Clinical
Trials.gov, ID: NCT03282955 on 14 September 2017.
Discussion
This prospective, randomized controlled clinical trial
aims to prove the safety and tolerability of an n-3
PUFA-enriched ILE during HPN in adult patients with
CIF and to show that the ILE containing n-3 PUFAs
(test IP) is comparable to the ILE containing SO/LCT
and MCT (1:1) with regard to liver function. Addition-
ally, the study should provide further evaluation of safety
and efficacy of the ILEs.
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Only very few RCTs on the use of ILEs in adult CIF
patients receiving HPN are published and, furthermore,
the data on the use of n-3 PUFA and their influence on
liver function are very limited. It was reported in a
multicenter clinical trial that a FO containing ILE is safe
and well-tolerated in CIF patients and leads to a de-
crease of liver values for total bilirubin, ALT and AST
after 4 weeks [26]. A recently published RCT comparing
four ILEs for 12 months showed that all tested ILEs were
safe and comparable regarding their influence on liver
function, but did not confirm a positive clinical impact
of FO [27]. Other published reports on the use of FO/n-
3 in adult CIF patients are only case reports or case
series and, thus, there is a clear need for more data from
randomized controlled trials.
The present study aims to include 160 stable adult CIF
patients. This sample size is one of the biggest chal-
lenges in this study since CIF is an “orphan” disease and
the rarest kind of organ failure. The prevalence of HPN
for CIF due to benign disease has been estimated to be
between 5 and 20/1,000,000 [3] and 3.25–66/1,000,000
[29] in Europe. A multicenter, multinational approach
was chosen to accomplish the statistically required sam-
ples size, and also to increase the external validity and
the international generalizability of the results.
The supply of PN for patients at home is subject to
thorough organized processes and in this respect there
are many differences between countries and even be-
tween hospitals within the same country. In this multi-
center, multinational clinical trial it is intended to follow
the individual standard procedure of PN preparation and
supply as far as possible. For HPN patients in the United
Kingdom (UK) several pharmacy service companies are
available, but for this clinical trial only one compound-
ing company was selected. This can be a limiting factor
for recruitment in the UK, and also requires consider-
ation when interpreting the data, in particular with re-
gard to the generalizability of the results for the UK
sites.
The primary endpoint is the combined change of the
liver function parameters bilirubin, ALT and AST. Lit-
erature reporting on the incidence of liver disease in
adults with CIF receiving long-term HPN varies in the
biochemical and/or histological parameters used to de-
fine liver dysfunction [15, 26, 30]. A consensus defin-
ition, that sets parameters for the truly standardized
diagnosis of IFALD is not available. We consider the
combined change of bilirubin, AST and ALT useful and
sensitive enough to detect and evaluate liver dysfunction.
In order to complete the standard liver panel, alkaline
phosphatase (ALP) and gamma-glutamyl transpeptidase
(GGT) are assessed as secondary endpoints.
Most study assessments are part of the routine moni-
toring practice for long-term HPN patients. Normally,
patients receiving HPN visit the outpatient clinic every
2–4 months. The intervals between the study visits are
shorter and additional blood samples are drawn to
analyze the primary endpoint centrally and for assess-
ment of the secondary parameters including FA patterns.
The questionnaire used for the subjective patient-
reported QoL (EQ-5D-5 L) is well-accepted. The diary
for documentation of investigational lipid infusion is
designed in a way that the required information can be
recorded with minimal effort. The prescription of the
investigational lipid during the study is according to the
prescription of the lipid before inclusion of the patient
into the study. Both IPs have market authorization and
have been used for years in different patient groups.
Given that the patients participating in the study are
dependent on nutritional treatment and the supply of
lipids, the risks associated with the IP administration are
assumed not to be higher than those when lipids are ad-
ministered in their regular treatment. Taking together
all these aspects, the burden and risks for patients are
expected to be very low and the study protocol has lim-
ited impact on patients’ daily lives.
In summary, the HOME study should provide data
from a considerable number of adult patients with CIF
receiving HPN and thus contribute to broaden the evi-
dence on the use of ILEs in HPN.
Trial status
Currently, the trial is in the recruitment phase. Recruitment
started on 8 January 2018 and the estimated completion
date will be in July 2021. The study protocol has the current
version 2.2, dated 5 November 2018. The change history is
given in the “Ethical approvals” section.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3994-z.
Additional file 1. Secondary study variables.
Additional file 2. Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist.
Abbreviations
AE : Adverse event; ALP: Alkaline phosphatase; ALT: Alanine transaminase;
AST: Aspartate transaminase; BMI: Body mass index; BW: Body weight;
CIF: Chronic intestinal failure; CU: Compounding unit; DHA: Docosahexaenoic
acid; eCRF: Electronic Case Report Form; EFA: Essential fatty acids;
EPA: Eicosapentaenoic acid; ESPEN: The European Society for Clinical
Nutrition and Metabolism; FA: Fatty acid; FAS: Full Analysis Set; FO: Fish oil;
GGT: Gamma-glutamyl transpeptidase; HPN: Home parenteral nutrition;
IFALD: Intestinal-failure-associated liver disease; ILE: Intravenous lipid
emulsion; IP: Investigational Product; IVS: Intravenously administered
supplementation; LA: Linoleic acid; LCT: Long-chain triglyceride;
MCT: Medium-chain triglyceride; n-3: Omega-3; n-6: Omega-6; OO: Olive oil;
PN: Parenteral nutrition; PUFA: Polyunsaturated fatty acid; QoL: Quality of life;
RBC: Red blood cell; RCT: Randomized controlled trial; SAE: Serious adverse
event; SAR: Serious adverse reaction; SD: Standard deviation; SO: Soybean oil;
SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials;
Klek et al. Trials          (2019) 20:808 Page 9 of 11
SUSAR: Suspected Unexpected Serious Adverse Reaction; VCAS: Valid Case
Analysis Set
Acknowledgements
The authors would like to thank Simone Keller, B. Braun Melsungen AG, for
medical writing services. We also thank all members of the HOME Study
Group for their participation in the trial.
HOME Study Group:
Alison Culkin (Lennard Jones Intestinal Rehabilitation Unit, St Mark’s Hospital,
Watford Road, Harrow HA1 3UJ, UK); Karolina Dabrowska (Samodzielny
Publiczny Szpital Kliniczny im. Prof. dr W. Orlowskiego, Oddzial Kliniczny
Zywienia i Chirurgii, ul. Czerniakowska 231, 00–416 Warszawa, Poland); Jane
Fletcher (University Hospitals Birmingham NHS Foundation Trust, Queen
Elizabeth Hospital, Mindelsohn Way, Birmingham B15 2TH, UK); Mariacristina
Guidetti (Chronic Intestinal Failure Center, Digestive Disease Department, St.
Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences, Uni-
versity of Bologna, Bologna 40,138, Italy); Angelique Huijbers (Department of
Gastroenterology and Hepatology, Geert Grooteplein 8, 6500 HB Nijmegen,
Netherlands); Krystyna Majewska (Samodzielny Publiczny Szpital Kliniczny im.
Prof. dr W. Orlowskiego, Oddzial Kliniczny Zywienia i Chirurgii, ul. Czernia-
kowska 231, 00–416 Warszawa, Poland); Anna Simona Sasdelli (Chronic Intes-
tinal Failure Center, Digestive Disease Department, St. Orsola-Malpighi
Hospital, Department of Medical and Surgical Sciences, University of Bologna,
Bologna 40,138, Italy).
Authors’ contributions
All authors made substantial intellectual contributions to the study
conception and design and have been involved in drafting the manuscript.
SK and AF revised the manuscript critically for important intellectual content.
All authors read and approved the final manuscript.
Funding
This clinical study is organized and financed by B. Braun Melsungen AG, Carl-
Braun Str. 1, 34212 Melsungen, Germany, the sponsor of this study. B. Braun
Melsungen AG organized protocol development, contracted a contract re-
search organization for clinical trial application, monitoring and collection/
analysis of study data, and provided medical writing services for this manu-
script. Test and reference IP are produced and delivered by B. Braun Melsun-
gen AG to all participating sites or concerned compounding unit.
Availability of data and materials
Not applicable
Ethics approval and consent to participate
The study protocol was initially approved in its version 1.0 dated 11 October
2016 by the Ethics Committee of the Radboud University Medical Centre
and the Centrale Commissie Mensgebonden Onderzoek (CCMO),
Netherlands, (No. NL59956.091.17), and by the Ethics Committee of the
University Hospital of Bologna, (No. 22/2017/O/sper) and the Agenzia Italiana
del Farmaco (reference to European Clinical Trials Database No: 2015–
000849-23), Italy. The Ethics Committee of the East Hospital Group Bâtiment
Pinel – South-East III CPP, France, requested an amendment in the exclusion
criteria (add exclusion criterion no. 16). The amended study protocol version
2.0, dated 20 June 2017 was approved by the French Ethics Committee (No.
2017–031 B) and the National Agency for the Safety of Medicines and Health
Products (ANSM), France, (No. 170301A-42), and after initial submission in
Poland by the Ethics Committee Regional Medical Association Kraków (No.
148/KBL/OIL/2017) and the Office for Registration of Medicinal Products,
Medical Devices and Biocidal Products (No. UR.DBL.BLE.4500.0276.2017.NK.1
1148/17). The substantial amendment was approved by the Ethics Commit-
tee of the University Hospital of Bologna on 20 September 2017, and by the
Ethics Committee of Radboud University Medical Centre on 28 September
2017. The study protocol version 2.1, dated 11 November 2017 including
non-substantial clarifications was initially approved by the London – Chelsea
Research Ethics Committee and Health Research Authority (18/LO/0569), and
the Medicines and Healthcare products Regulatory Agency (03551/0300/
001–0001), UK. The study protocol in its current version 2.2, dated 5 Novem-
ber 2018 including one non-substantial change was notified to the Ethics
Committee and Health Research Authority in the UK for confirmation of clas-
sification as non-substantial. The non-substantial changes do not impact the
conduct of the trial.
Written informed consent has been obtained from all patients before
enrollment in the clinical trial.
Consent for publication
Not applicable
Competing interests
SK received honoraria as a lecturer from Baxter, BBraun, Fresenius-Kabi, Nes-
tle, Nutricia and Shire. CC declares conflicting interests with Baxter and
BBraun. SC received educational sponsorship from Fresenius-Kabi/Calea and
Shire/Takeda and honoraria from Baxter and Novartis. SG received consult-
ancy honoraria and funding for conferences from Takeda and Shire. MK re-
ceived honoraria as a speaker from Baxter, Fresenius-Kabi, and Shire. LP
received an advisory board grant from Baxter, Fresenius-Kabi and Shire, and
an educational grant from SEDA. FR declares that he has no competing inter-
ests. JS received honoraria as a lecturer from Baxter, BBraun, Fresenius-Kabi,
Nestle, Nutricia and Shire. KS received honoraria as a lecturer from Baxter,
BBraun, Fresenius-Kabi and Nutricia. GW received research grants from
Fresenius-Kabi, Baxter, BBraun and Geistlich Pharma. AF is a member of the
speakers’ bureau for Baxter, BBraun, Dr Falk Pharma, and Fresenius-Kabi. NL
and BG are employed by B. Braun Melsungen AG.
Author details
1Stanley Dudrick’s Memorial Hospital, General and Oncology Surgery Unit, 15
Tyniecka Street, 32-050 Skawina, Poland. 2Hospices Civils de Lyon, Centre
Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre-Benite,
France. 3GI Medicine – University Hospitals Birmingham NHS Foundation
Trust, Queen Elizabeth Hospital, Mindelsohn Way, Birmingham B15 2TH, UK.
4St Mark’s Hospital, Northwick Park, Watford Road, Harrow HA1 3UJ, UK.
5Wojewódzki Specjalistyczny Szpital im. M. Pirogowa w Łodzi, Oddział
Chirurgii Ogólnej i Naczyniowej, ul. Wólczańska 191/195, 90-531 Łódź,
Poland. 6Department of Medical and Surgical Science, University of Bologna,
St. Orsola-Malpighi Hospital, Via Massarenti, 9, 40138 Bologna, Italy.
7University College Hospital, 250 Euston Road, London NW1 2PG, UK.
8Samodzielny Publiczny Szpital Kliniczny im. Prof. dr W. Orlowskiego, Oddzial
Kliniczny Zywienia i Chirurgii, ul. Czerniakowska 231, 00-416 Warszawa,
Poland. 9Radboud Universitair Medisch Centrum, Afdeling Maag-, Darm- en
Leverziekten, Postbus 9101, 6500 HB Nijmegen, The Netherlands. 10Medical
Scientific Affairs, B. Braun Melsungen AG, Carl-Braun-Str. 1, 34212 Melsungen,
Germany. 11Faculty of Medicine and Health Sciences, University of East
Anglia, Norwich NR4 7TJ, UK.
Received: 27 September 2019 Accepted: 12 December 2019
References
1. Staun M, Pironi L, Bozzetti F, Baxter J, Forbes A, Joly F, et al. ESPEN
Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult
patients. Clin Nutr. 2009;28(4):467–79 Epub 2009 May 22.
2. Pironi L, Arends J, Baxter J, Bozzetti F, Peláez RB, Cuerda C, et al. Acute
Intestinal Failure Special Interest Groups of ESPEN. ESPEN endorsed
recommendations. Definition and classification of intestinal failure in adults.
Clin Nutr. 2015;34(2):171–80. https://doi.org/10.1016/j.clnu.2014.08.017 Epub
2014 Sep 21.
3. Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, et al.
Home Artificial Nutrition and Chronic Intestinal Failure Special Interest
Group of ESPEN. ESPEN guidelines on chronic intestinal failure in adults. Clin
Nutr. 2016;35(2):247–307. https://doi.org/10.1016/j.clnu.2016.01.020 Epub
2016 Feb 8.
4. Jeppesen PB, Høy CE, Mortensen PB. Essential fatty acid deficiency in
patients receiving home parenteral nutrition. Am J Clin Nutr. 1998;
68(1):126–33.
5. Wanten GJ. Parenteral lipids: safety aspects and toxicity. World Rev Nutr
Diet. 2015;112:63–70. https://doi.org/10.1159/000365434 Epub 2014 Nov 24.
6. Clayton PT, Whitfield P, Iyer K. The role of phytosterols in the
pathogenesis of liver complications of pediatric parenteral nutrition.
Nutrition. 1998;14(1):158–64.
7. Baldermann H, Wicklmayr M, Rett K, Banholzer P, Dietze G, Mehnert H.
Changes of hepatic morphology during parenteral nutrition with lipid
emulsions containing LCT or MCT/LCT quantified by ultrasound. JPEN J
Parenter Enteral Nutr. 1991;15(6):601–3.
Klek et al. Trials          (2019) 20:808 Page 10 of 11
8. Rubin M, Moser A, Vaserberg N, Greig F, Levy Y, Spivak H, et al. Structured
triacylglycerol emulsion, containing both medium- and long-chain fatty
acids, in long-term home parenteral nutrition: a double-blind randomized
cross-over study. Nutrition. 2000;16(2):95–100.
9. Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, et al.
Parenteral nutrition with fish oil modulates cytokine response in patients with
sepsis. Am J Respir Crit Care Med. 2003;167(10):1321–8 Epub 2003 Feb 25.
10. Heller AR, Rössler S, Litz RJ, Stehr SN, Heller SC, Koch R, Koch T. Omega-3
fatty acids improve the diagnosis-related clinical outcome. Crit Care Med.
2006;34(4):972–9.
11. Wichmann MW, Thul P, Czarnetzki HD, Morlion BJ, Kemen M, Jauch KW.
Evaluation of clinical safety and beneficial effects of a fish oil containing
lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized,
multicenter trial. Crit Care Med. 2007;35(3):700–6.
12. Wang J, Yu JC, Kang WM, Ma ZQ. Superiority of a fish oil-enriched emulsion
to medium-chain triacylglycerols/long-chain triacylglycerols in
gastrointestinal surgery patients: a randomized clinical trial. Nutrition. 2012;
28(6):623–9. https://doi.org/10.1016/j.nut.2011.08.004 Epub 2011 Nov 23.
13. Grau-Carmona T, Bonet-Saris A, García-de-Lorenzo A, Sánchez-Alvarez C,
Rodríguez-Pozo A, Acosta-Escribano J, et al. Influence of n-3
polyunsaturated fatty acids enriched lipid emulsions on nosocomial
infections and clinical outcomes in critically ill patients: ICU lipids study. Crit
Care Med. 2015;43(1):31–9. https://doi.org/10.1097/CCM.0000000000000612.
14. Eltweri AM, Thomas AL, Metcalfe M, Calder PC, Dennison AR, Bowrey DJ,
et al. Potential applications of fish oils rich in omega-3 polyunsaturated fatty
acids in the management of gastrointestinal cancer. Clin Nutr. 2016. https://
doi.org/10.1016/j.clnu.2016.01.007 Epub ahead of print.
15. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease
and contributing factors in patients receiving home parenteral nutrition for
permanent intestinal failure. Ann Intern Med. 2000;132(7):525–32.
16. Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, et al. Safety and efficacy of
a fish-oil-based fat emulsion in the treatment of parenteral nutrition-
associated liver disease. Pediatrics. 2008;121(3):e678–86. https://doi.org/10.
1542/peds.2007-2248.
17. Goulet O, Antébi H, Wolf C, Talbotec C, Alcindor LG, Corriol O, Lamor M,
et al. A new intravenous fat emulsion containing soybean oil, medium-
chain triglycerides, olive oil, and fish oil: a single-center, double-blind
randomized study on efficacy and safety in pediatric patients receiving
home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010;34(5):485–95.
https://doi.org/10.1177/0148607110363614.
18. Diamond IR, Grant RC, Pencharz PB, de Silva N, Feldman BM, Fitzgerald P,
et al. Preventing the progression of intestinal failure-associated liver disease
in infants using a composite lipid emulsion: a pilot randomized controlled
trial of SMOFlipid. JPEN J Parenter Enteral Nutr. 2016;41(5):866–77.
19. Mundi MS, Pattinson A, McMahon MT, Davidson J, Hurt RT. Prevalence of
home parenteral and enteral nutrition in the United States. Nutr Clin Pract.
2017;32(6):799–805.
20. Burns DL, Gill BM. Reversal of parenteral nutrition-associated liver disease
with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on
home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2013;37(2):274–80.
https://doi.org/10.1177/0148607112450301 Epub 2012 Jun 8.
21. Venecourt-Jackson E, Hill SJ, Walmsley RS. Successful treatment of parenteral
nutrition-associated liver disease in an adult by use of a fish oil-based lipid
source. Nutrition. 2013;29(1):356–8. https://doi.org/10.1016/j.nut.2012.07.009
Epub 2012 Nov 7.
22. Hurt RT, Mundi MS. Use of mixed-oil fat emulsion to improve intestinal
failure-associated liver disease in long-term home parenteral nutrition: A
case report. JPEN J Parenter Enteral Nutr. 2017;41(1_Suppl):17S–9S. https://
doi.org/10.1177/0148607117741870 Epub 2017 Nov 17.
23. Xu Z, Li Y, Wang J, Wu B, Li J. Effect of omega-3 polyunsaturated fatty acids
to reverse biopsy-proven parenteral nutrition-associated liver disease in
adults. Clin Nutr. 2012;31(2):217–23. https://doi.org/10.1016/j.clnu.2011.10.
001 Epub 2011 Oct 27.
24. Mundi MS, McMahon MT, Carnell JJ, Hurt RT. Long-term use of mixed-oil
lipid emulsion in adult home parenteral nutrition patients: a case series.
Nutr Clin Pract. 2018;33(6):851–7. https://doi.org/10.1002/ncp.10014 Epub
2018 Feb 13.
25. Jones CJ, Calder PC. Influence of different intravenous lipid emulsions on
fatty acid status and laboratory and clinical outcomes in adult patients
receiving home parenteral nutrition: a systematic review. Clin Nutr. 2018;
37(1):285–91. https://doi.org/10.1016/j.clnu.2016.12.026 Epub 2016 Dec 31.
26. Klek S, Chambrier C, Singer P, Rubin M, Bowling T, Staun M, et al. Four-week
parenteral nutrition using a third generation lipid emulsion (SMOFlipid)—a
double-blind, randomised, multicentre study in adults. Clin Nutr. 2013;32(2):
224–31. https://doi.org/10.1016/j.clnu.2012.06.011 Epub 2012 Jul 12.
27. Klek S, Szczepanek K, Scislo L, Walewska E, Pietka M, Pisarska M, Pedziwiatr
M. Intravenous lipid emulsions and liver function in adult chronic intestinal
failure patients: results from a randomized clinical trial. Nutrition. 2018;55–
56:45–50. https://doi.org/10.1016/j.nut.2018.03.008 Epub 2018 Mar 22.
28. Lehmacher W, Wassmer G, Reitmeir P. Procedures for two-sample
comparison with multiple endpoints controlling the Experimentwise Error
Rate. Biometrics. 1991;47:511–21.
29. Van Gossum A, on behalf of the ESPEN HAN&CIF group. Home artificial
nutrition in Europe. In: Bozzetti F, Staun M, Van Gossum A, editors. Home
parenteral nutrition. Oxon: CABI International; 2015. p. 14–24.
30. Tillman EM. Review and clinical update on parenteral nutrition-associated
liver disease. Nutr Clin Pract. 2013;28(1):30–9. https://doi.org/10.1177/
0884533612462900 Epub 2012 Oct 19.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Klek et al. Trials          (2019) 20:808 Page 11 of 11
